NASDAQ · SPRC
Healthcare · Biotechnology
$4.53
Up+$0.02 (+0.44%)
Updated Sep 22, 2026, 4:05 AM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SPRC closed at $4.53 after 20 trading sessions, down 31.98% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 21, 2026 | $4.6427 | $4.6427 | $4.45 | $4.53 | 4.75K |
| Sep 18, 2026 | $4.48 | $4.64 | $4.45 | $4.51 | 3.06K |
| Sep 17, 2026 | $5.1893 | $5.1893 | $4.39 | $4.45 | 24.21K |
| Sep 16, 2026 | $4.88 | $4.88 | $4.65 | $4.68 | 9.65K |
| Sep 15, 2026 | $5.14 | $5.14 | $4.72 | $4.76 | 12.61K |
| Sep 14, 2026 | $4.9601 | $5.08 | $4.90 | $4.91 | 4.97K |
| Sep 11, 2026 | $5.27 | $5.27 | $5.00 | $5.08 | 11.58K |
| Sep 10, 2026 | $4.83 | $5.1799 | $4.83 | $4.95 | 15.3K |
| Sep 9, 2026 | $5.11 | $5.11 | $4.95 | $4.95 | 16.97K |
| Sep 8, 2026 | $5.18 | $5.35 | $5.06 | $5.10 | 6.96K |
| Sep 4, 2026 | $5.17 | $5.435 | $5.15 | $5.29 | 27.68K |
| Sep 3, 2026 | $5.61 | $5.9466 | $5.0701 | $5.13 | 41.25K |
| Sep 2, 2026 | $5.80 | $5.9999 | $5.41 | $5.85 | 49.3K |
| Sep 1, 2026 | $6.062 | $6.22 | $5.50 | $5.67 | 90.29K |
| Aug 31, 2026 | $6.68 | $6.88 | $6.50 | $6.63 | 63.07K |
| Aug 28, 2026 | $6.75 | $6.82 | $6.50 | $6.58 | 84.13K |
| Aug 27, 2026 | $6.69 | $6.775 | $6.54 | $6.62 | 11.29K |
| Aug 26, 2026 | $6.665 | $7.19 | $6.60 | $6.74 | 13.98K |
| Aug 25, 2026 | $6.62 | $6.855 | $6.61 | $6.69 | 7.19K |
| Aug 24, 2026 | $6.92 | $7.039 | $6.5252 | $6.66 | 11.44K |
The latest Smart Investors Daily articles mentioning SPRC.
SPRC research
Company profile and research snapshot.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Sep 2, 2026
Gainers Gelteq (NASDAQ:GELS) stock moved upwards by 20.3% to $0.84 during Wednesday's after-market session. The company's market cap stands at $5.6 million. Nyxoah (NASDAQ:NYXH) shares increased by 12.58% to
Yahoo · Sep 2, 2026
This Strategic Engagement is Designed to Strengthen NeuroThera's U.S. Market Position, Visibility Among Key U.S. Federal Stakeholders, Reinforce the Clinical and PublicHealth Importance of Advancing New Treatment Options for Adult Tourette Syndrome T...
Benzinga · Sep 2, 2026
This strategic engagement is designed to strengthen NeuroThera’s U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public‑health importance of advancing new treatment
ChartMill · Aug 31, 2026
Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SPRC.
No results
No recent SID articles mention SPRC.
